Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.58 |
| ▸ | ABL1 | P00519 | 3/20 | 0.56 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30494400 | 0.82 | CYP11B1 (0.58) | CYP11B1CYP11B2ABL1SLC22A12 | |
| SCHEMBL26462960 | 0.82 | CYP11B1 (0.58) | CYP11B1CYP11B2ABL1SLC22A12 | |
| SCHEMBL26464927 | 0.81 | ABL1 (0.59) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 | |
| SCHEMBL30494281 | 0.81 | ABL1 (0.59) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 | |
| SCHEMBL10273624 | 0.77 | ABL1 (0.55) | CYP11B1CYP11B2ABL1PRMT5WDR77 | |
| SCHEMBL30494340 | 0.77 | ABL1 (0.55) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 | |
| SCHEMBL26463262 | 0.77 | ABL1 (0.55) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 | |
| SCHEMBL5302293 | 0.76 | AAK1 (0.53) | CYP11B1CYP11B2CYP3A4 | |
| SCHEMBL30494267 | 0.75 | PRMT5 (0.53) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 | |
| SCHEMBL26464741 | 0.74 | ABL1 (0.49) | CYP11B1CYP11B2ABL1MAP4K1PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-07-24 | — | — | US | disclosed |
| EP-4423067-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2024-09-04 | — | — | EP | disclosed |
| CN-118176181-A | SARM1 modulators, their preparation and use | 维泰瑞隆有限公司 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023072026-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023072026-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236613-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, ADRM1, SMN1; SMN2 | CYP11B1 4003/4885CYP11B2 4133/4885ABL1 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.